Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Gains from Investment Securities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Gains from Investment Securities for 14 consecutive years, with -$3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$3.4 million, compared with a TTM value of $259.2 million through Dec 2025, down 43.85%, and an annual FY2024 reading of $271.6 million, up 35.26% over the prior year.
  • Gains from Investment Securities was -$3.4 million for Q3 2025 at Neurocrine Biosciences, down from $262.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $262.6 million in Q4 2024 and bottomed at -$14.2 million in Q2 2023.
  • Average Gains from Investment Securities over 4 years is $92.0 million, with a median of $16.0 million recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 31.96% in 2024, while the deepest fall reached 31.96% in 2024.
  • Year by year, Gains from Investment Securities stood at $16.0 million in 2021, then soared by 1143.75% to $199.0 million in 2023, then skyrocketed by 31.96% to $262.6 million in 2024, then plummeted by 101.29% to -$3.4 million in 2025.
  • Business Quant data shows Gains from Investment Securities for NBIX at -$3.4 million in Q3 2025, $262.6 million in Q4 2024, and $199.0 million in Q4 2023.